Download - David Tyas Global HEOR - Lundbeck
![Page 1: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/1.jpg)
Example of Health Technology Assessment (HTA)
of a therapy for the reduction of alcohol
consumption
David TyasGlobal HEOR - Lundbeck
![Page 2: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/2.jpg)
Contents• Introduction into a HTA process
• Use SMC as an example but equally could be from many other countries
• Summary of our submission• Main argument• Types of analysis• Clarification question stage
• Summary of questions (what sort)• Final recommendation
2
![Page 3: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/3.jpg)
Economic Evaluations in EuropeNorway: Pharmacoeconomic data required for reimbursement; official guidelines in operation.
Finland:Pharmacoeconomic evidence mandatory for evaluating newtherapies for reimbursement and may also be requested for existing therapies.
Sweden:Cost-effectiveness data required for reimbursement.
Denmark:Cost-effectiveness data may be requested for reimbursement decisions.
UK:NICE, SMC, and AWMSG evaluates the cost effectiveness of medicines.
Germany:Guidelines prepared. Institute for Quality and Efficiency in the Health Service established in 2004.
France:Not a formal requirement but increasingly used in reimbursement decisions. Guidelines prepared.
Spain:Health technology assessment at a regional level.
Portugal:Cost-effectiveness data incorporated into reimbursement decisions.
Italy:Cost-effectiveness considered in pricing and reimbursement decisions.
Greece: Guidelines for pharmacoeconomic studies prepared; cost-effectiveness data may be requested.
Belgium: Formal requirement for economic evaluation.
Netherlands:Pharmacoeconomic evidence explicitly required for reimbursement of new products.
Ireland: Guidelines for pharmacoeconomic studies prepared; cost-effectiveness data may be requested.
Poland: C/E and BIA may be requested. HTA agency.
3
![Page 4: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/4.jpg)
Manufacturers submission
Clarification questions
Draft advice
Final recommendati
on
SMC process
4
![Page 5: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/5.jpg)
Example of a HTA submission dossier- SMC requirements
Chapter 1 Registration DetailsChapter 2 Overview and Positioning Chapter 3 Comparative EfficacyChapter 4 Comparative SafetyChapter 5 Clinical EffectivenessChapter 6 Pharmaco-Economic EvaluationChapter 7 Resource ImplicationsTotal ~ 100 pages
5
![Page 6: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/6.jpg)
NalmefeneMain arguments and data
6
![Page 7: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/7.jpg)
Indication
Nalmefene is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification.
WHO categoryTotal Alcohol Consumption
(g/day)Women Men
Very high-risk consumption > 60 > 100High-risk consumption 40–60 60–100Medium-risk consumption 20–40 40–60Low-risk consumption 1–20 1–40
7
![Page 8: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/8.jpg)
Relative risk for all-cause mortality by average daily intake of alcohol
8
![Page 9: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/9.jpg)
9
![Page 10: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/10.jpg)
Place in therapy
Stages of alcohol abuse/ dependence
Early Middle Late
Brief intervention
Reduction
Abstinence
Trea
tmen
t int
ensi
ty
10
![Page 11: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/11.jpg)
Clinical efficacy
Study name Study duration Patients enrolled High drinking risk
ESENSE 1(Mann 2013; Wim van den Brink 2013)
24-week604
(306+298)350
180+170
ESENSE 2(Gual 2013; Wim van den Brink 2013)
24-week718
(358+360)317
(155+162)
SENSE(Wim van den Brink 2014)
52-week675
(509+166)187
3 RCTs in patients with alcohol dependence
Mann et al. 2013. Biol Psychiatry 73(8) 706-713Gual et al. 2013. Eur Neuropsychopharmacol 23(11) 1432-42Wim van den Brink et al. 2014. J PsychopharmacolWim van den Brink et al. 2013. Alcohol and Alcoholism. 1–9 11
![Page 12: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/12.jpg)
Pharmaco Economic analysis
Objective:• To show nalmefene is cost-
effective
Treatment alternatives:• Nalmefene + psychosocial
support• Psychosocial support alone
Perspective:• Healthcare system
Time horizon:• 1 year: period covered by RCTs• 5 years
Population:• nalmefene indication as informed
by phase III clinical programme
12
![Page 13: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/13.jpg)
General concept of the model
Decreasecosts
IncreaseQALYs
Reduction of alcohol intake
Quality-Adjusted Life Year (QALY)
QALY=patient quality of life * patient survival
Reduction of alcohol-attributable harms and mortality
Severe morbidities and injuries considered:
• Transport injuries• Injuries other than
transport• Ischaemic heart
disease• Ischaemic stroke• Liver cirrhosis• Pancreatitis• lower respiratory
infections13
![Page 14: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/14.jpg)
Clarification questions
14
![Page 15: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/15.jpg)
15
1. Patient discontinuation2. Calculation of number of days taking therapy3. Application of utility in the model4. Proportion who receive care at a specialist level5. Real world discussion of relapse rate
![Page 16: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/16.jpg)
Final recommendation
16
![Page 17: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/17.jpg)
17
![Page 18: David Tyas Global HEOR - Lundbeck](https://reader035.vdocuments.mx/reader035/viewer/2022081422/56816178550346895dd10675/html5/thumbnails/18.jpg)
Questions….